Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Palliative and end-of-life care in advanced Parkinson's disease and multiple sclerosis

Colin W Campbell, Edward JS Jones and Jane Merrills
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.10-3-290
Clin Med June 2010
Colin W Campbell
Saint Catherine's Hospice, Scarborough
Roles: Consultant in palliative medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: colin.campbell@st-catherineshospice.org.uk
Edward JS Jones
Scarborough and North East Yorkshire Healthcare NHS Trust, Scarborough Hospital
Roles: Consultant physician with an interest in care of the elderly
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane Merrills
Hull Royal Infirmary
Roles: Clinical nurse specialist in Parkinson's disease
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading
Key Words
  • best interests
  • multiple sclerosis
  • palliative
  • Parkinson's disease
  • terminal

Key Points

Palliative care in advanced Parkinson's disease (PD) and multiple sclerosis (MS) recognises the need to move from attempting to control function to affording comfort measures

Admission to an acute hospital can be highly disruptive to the nursing and drug routines for these patients

Advanced disease can lead to cognitive changes in MS, and in PD to dementia and hallucinations, each of which can rob patients of the opportunity to express their wishes and preferences as their disease progresses further

It can be empowering for those patients who still have capacity, sensitively to discuss whether they would wish to receive life-prolonging treatments as their disease progresses, such as intravenous antibiotics, percutaneous endoscopic gastrostomy feeding tubes and artificial ventilation

The terminal phase of PD and MS usually occurs against a backdrop of more rapid global decline and increasingly severe disability. The terminal event is often an acute episode of sepsis causing death over a few days

Patients with advanced Parkinson's disease (PD) and multiple sclerosis (MS) can present with challenging clinical problems when admitted to acute hospitals. They are susceptible to life-threatening complications, most commonly sepsis, which arise against a backdrop of progressive decline in overall function. Both PD and MS may be complicated by cognitive impairment, swallowing or speech problems and refractory pain syndromes.1,2 Robust evidence supporting treatment decisions in advanced disease is lacking, but recent national guidelines recognise the importance of shifting goals towards a palliative approach as the disease becomes more advanced.3–6

Importance of communication

Prompt and effective discussion between the patient's general practitioner and secondary care clinicians may both prevent inappropriate hospital admissions and achieve treatment decisions in the patient's best interests. Drawing on the strengths of multidisciplinary team working invariably ensures that patients receive better care. The key, however, to optimising care is taking time adequately to hear the patient's wishes before they might lose capacity.

Estimating prognosis

Both in advanced PD and MS it is difficult to anticipate life expectancy, but the rate of overall deterioration is an important indicator of prognosis. Patients are particularly at risk of dying from aspiration pneumonia, urinary tract infections, complications from falls and fractures, and sepsis secondary to pressure ulcers. These are all commoner the more advanced the disease. Even so, some very disabled patients will live for many years while others may succumb quite suddenly from an episode of sepsis or, less commonly, from a pulmonary embolus. The unpredictable disease trajectory makes planning for the terminal event particularly difficult and most patients die in hospital rather than at home.7

Common themes and contrasts in advanced PD and MS

Cognitive/psychiatric

  • Cognitive changes are common in MS, with loss of verbal fluency, memory problems and difficulty with concentration.8

  • PD dementia is common, characterised by illusions, visual hallucinations, visuospatial deficits, attentional and dysexecutive deficits.9 PD dementia can respond to acetylcholinesterase inhibitors.10 Hallucinations may respond to reduction in PD medication, particularly amantadine, monoamine oxidase type B inhibitors (MAOI-B), cholinergic medication and dopamine agonists.

  • Depression is common in both illnesses. It may respond to selective serotonin reuptake inhibitors (SSRIs). In PD, optimisation of dopaminergic therapy and tricyclic antidepressants have also been shown to have benefit.11 SSRIs should not be co-administered with MAOI-Bs because of the risk of serotonin syndrome.

Bulbar symptoms

  • Hypophonia in PD and dysarthria in MS can make communication difficult and lead to immense frustration for patients and carers.12

  • Swallowing problems are associated with aspiration. Early expert assessment by a speech and language therapist is essential. Aspiration may initially be silent without apparent systemic effects, but the situation can change within a few hours as the patient develops systemic signs of sepsis.

  • Drooling of saliva is more common in PD. It can be managed by ultrasound guided salivary gland botulinum toxin injections, topical atropine 1% drops applied to the tongue or topical hyoscine patches.

Pain

Pain can be a disabling feature of PD2 and may have a variety of causes including central pain and dystonia.

  • Neuropathic pain in the limbs or face is frequently difficult to treat in MS.13 Amitriptyline and anticonvulsant drugs like gabapentin are often employed. However, both groups of drugs are less well tolerated in MS and there are often unacceptable anticholinergic side effects from tricyclics and sedation and ataxia from anticonvulsants.

  • Spasticity in MS can cause painful spasms and limb jerking, both of which can be particularly troublesome during the night. Antispasticity drugs have a variable degree of success and tend to cause sedation and ataxia. Limb contractures are a sign of advanced disease.

  • Pressure ulcers, usually over bony prominences, can be related to loss of mobility and inadequate nutrition.

Decision making

Broaching the topic of life-prolonging treatments is best done when the patient is relatively well and still has capacity for the particular decision. No one should be coerced into advance care planning but some patients will feel more in control having signed an advance decision (refusing specified treatment) (Table 1).14,15

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Pertinent topics to consider in advance decisions (refusing treatment) in Parkinson's disease and multiple sclerosis.

Decision making in the acute situation

For patients who lack capacity and are acutely unwell, there is a requirement to act in the patient's ‘best interests’ as prescribed by the Mental Capacity Act 2005 (Table 2).16 Optimum decision making in advanced PD and MS revolves around ‘trying to get it right’ for the individual patient. As far as possible, this should be what the patient wants or, if they have lost capacity, would have wanted. The patient's previous experience of hospital admissions may influence their preferences.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2.

Making ‘best interests’ decisions, as described in the Mental Capacity Act 2005.16

Withdrawing/withholding treatment and practical symptom management17

As the patient becomes increasingly bedbound, sensitive discussions need to take place with the patient and family about altering the focus of care.5 In both diseases, the aim of treatment shifts from maximising function to minimising suffering and aiming for the patient's comfort and dignity. Common goals are:

  • freedom from pain

  • relieving anxiety and agitation (particularly in PD)

  • dealing with troublesome symptoms including:

    • drooling in PD

    • constipation

    • bladder spasms

    • insomnia.

One of the features of advanced PD is the inability to tolerate sufficient dopaminergic medication.18 In both PD and MS it is appropriate to minimise oral medication, particularly statins, antihypertensives and bulk-forming laxatives. Practical suggestions in managing complications for the acute physician are given in Table 3.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 3.

Tips for the acute medical take.

Managing the terminal phase

When the terminal phase can be anticipated by an acceleration in the patient's global deterioration, a decision may have been taken with the patient and family not to treat further episodes of infection. A careful check for specific symptoms should be sought from the patient directly or from observing the patient for any signs of distress. Close family members will often recognise signs of unspoken distress. The views of experienced clinical staff may determine if the patient is frightened, in pain or has different nursing requirements.

For patients unable to swallow in the terminal stage, medication can be administered subcutaneously as needed or continuously using a syringe driver.19 Medication can be given, if necessary, to relieve specific symptoms as follows:

  • midazolam for fear or agitation

  • hyoscine butylbromide for drooling or chesty secretions

  • morphine for pain

If pain is present, a sufficient dose of morphine should be used to relieve it but without causing undesirable opioid side effects.

  • © 2010 Royal College of Physicians

References

  1. ↵
    1. Higginson IJ,
    2. Hart S,
    3. Silber E,
    4. Burman R,
    5. Edmonds P
    . Symptom prevalence and severity in people severely affected by multiple sclerosis. J Palliat Care 2006;22:158–65
    OpenUrlPubMed
  2. ↵
    1. Lee MA,
    2. Walker RW,
    3. Hildreth TJ,
    4. Prentice WM
    . A survey of pain in idiopathic Parkinson's disease. J Pain Sympton Manage 2006;32:462–9doi:10.1016/j.jpainsymman.2006.05.020doi:10.1016/j.jpainsymman.2006.05.020
    OpenUrlCrossRefPubMed
  3. ↵
    1. National Institute for Health and Clinical Excellence
    . Management of multiple sclerosis in primary and secondary care, CG8 London: NICE, 2003
    1. National Institute for Health and Clinical Excellence
    . Parkinson's disease: diagnosis and management in primary and secondary care, CG35 London: NICE, 2006
  4. ↵
    Royal College of Physicians, National Council for Palliative Care and British Society of Rehabilitation Medicine. Long-term neurological conditions: management at the interface between neurology, rehabilitation and palliative care London: RCP, 2008
  5. ↵
    1. Department of Health
    . The National Service Framework for long term conditions London: DH, 2005
  6. ↵
    1. Snell K,
    2. Pennington S,
    3. Lee M,
    4. Walker R
    . The place of death in Parkinson's disease. Age Ageing 2009;38:617–9doi:10.1093/ageing/afp123doi:10.1093/ageing/afp123
    OpenUrlFREE Full Text
  7. ↵
    1. Bobholz JA,
    2. Rao SM
    . Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 2003;16:283–8doi:10.1097/00019052-200306000-00006doi:10.1097/00019052-200306000-00006
    OpenUrlCrossRefPubMed
  8. ↵
    1. Dubois B,
    2. Burn D,
    3. Goetz C,
    4. et al
    . Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Move Disord 2007;22:2314–24doi:10.1002/mds.21844doi:10.1002/mds.21844
    OpenUrlCrossRefPubMed
  9. ↵
    1. Emre M,
    2. Aarsland D,
    3. Albanese A,
    4. et al
    . Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509–18doi:10.1056/NEJMoa041470doi:10.1056/NEJMoa041470
    OpenUrlCrossRefPubMed
  10. ↵
    1. Menza M,
    2. Dobkin RD,
    3. Marin H,
    4. et al
    . A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886–92doi:10.1212/01.wnl.0000336340.89821.b3doi:10.1212/01.wnl.0000336340.89821.b3
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Goy ER,
    2. Carter JH,
    3. Ganzini L
    . Parkinson disease at the end of life: caregiver perspectives. Neurology 2007;69:611–2doi:10.1212/01.wnl.0000266665.82754.61doi:10.1212/01.wnl.0000266665.82754.61
    OpenUrlFREE Full Text
  12. ↵
    1. Kalia LV,
    2. O'Connor PW
    . Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Mult Scler 2005;11:322–7doi:10.1191/1352458505ms1168oadoi:10.1191/1352458505ms1168oa
    OpenUrlAbstract/FREE Full Text
  13. ↵
    www.adrtnhs.co.uk/index.html.
  14. ↵
    1. Campbell C,
    2. Partridge R
    . Artificial nutrition and hydration. Guidance in end of life care for adults London: National Council for Palliative Care, 2007
  15. ↵
    1. Chapman S
    . The Mental Capacity Act in practice: guidance for end of life care London: National Council for Palliative Care, 2008
  16. ↵
    1. British Medical Association
    . Withholding and withdrawing life-prolonging medical treatment: guidance for decision making. 2nd edn. OxfordBlackwell, 2003
  17. ↵
    1. Thomas S,
    2. MacMahon D
    . Parkinson's disease, palliative care and older people: Part 1. Nurs Older People 2004;16:22–6
    OpenUrlPubMed
  18. ↵
    1. British National Formulary
    . Prescribing in palliative care London: BNF, 2009
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Palliative and end-of-life care in advanced Parkinson's disease and multiple sclerosis
Colin W Campbell, Edward JS Jones, Jane Merrills
Clinical Medicine Jun 2010, 10 (3) 290-292; DOI: 10.7861/clinmedicine.10-3-290

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Palliative and end-of-life care in advanced Parkinson's disease and multiple sclerosis
Colin W Campbell, Edward JS Jones, Jane Merrills
Clinical Medicine Jun 2010, 10 (3) 290-292; DOI: 10.7861/clinmedicine.10-3-290
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Importance of communication
    • Estimating prognosis
    • Common themes and contrasts in advanced PD and MS
    • Decision making
    • Managing the terminal phase
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Palliative care in people with idiopathic Parkinson's disease who die in hospital
  • Triggers in advanced neurological conditions: prediction and management of the terminal phase
  • Google Scholar

More in this TOC Section

  • Advance care planning
  • Palliative and end-of-life care for patients with chronic heart failure and chronic lung disease
  • Ethical and legal issues in end-of-life care
Show more CME Palliative Medicine

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians